GeneDx Investors Face August Deadline in Securities Fraud Class Action
Investors who held GeneDx Holdings Corp. stock during the past year face an August 3, 2026, deadline to join a class action lawsuit. The litigation centers on allegations that the company misled shareholders regarding the integration of Fabric Genomics, ultimately triggering a 49% single-day stock price collapse.
The legal action, filed by Hagens Berman Sobol Shapiro LLP, targets a period between April 16, 2025, and May 4, 2026. Plaintiffs allege that GeneDx executives promoted the acquisition of Fabric Genomics as an AI-driven catalyst for growth and software-based revenue, while concealing significant operational disconnects and integration failures. These internal hurdles reportedly compromised the company's financial performance throughout the class period.
The facade of synergy crumbled on May 4, 2026, when GeneDx released first-quarter results that missed revenue estimates and forced a sharp reduction in full-year guidance. The company disclosed a $31.2 million impairment charge related to the Fabric unit—effectively erasing 94% of the original acquisition cost. Investors reacted to the news by offloading shares, causing the stock price to plunge from $67.93 to $34.51 in one trading session. Reed Kathrein, the Hagens Berman partner overseeing the investigation, stated that the firm is scrutinizing the full scope of management's public claims regarding the supposed AI efficiencies that never materialized.
Comments (0)
No comments yet. Be the first!